Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1

被引：7

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Chang, Edmund ^{[1
]}

Perbost, Regis ^{[3
]}

Scholler, Nathalie ^{[1
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Milletti, Francesca ^{[1
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Marseille, France

[3] HalioDx, Paris, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT153

引用

页数：3

共 50 条

[31] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
Kenderian, Saad S.
Oluwole, Olalekan O.
McCarthy, Philip L.
Reshef, Ran
Shiraz, Parveen
Ahmed, Omar
Le Gall, John
Nahas, Myrna
Tang, Lily
Neelapu, Sattva S.
BLOOD, 2020, 136
[32] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[33] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
Sun, Jennifer
BLOOD, 2018, 132
[34] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Herrera, Alex F.
Westin, Jason R.
Lee, Jennifer
Rossi, John M.
Sun, Jennifer
Zheng, Lianqing
Avanzi, Mauro P.
Roberts, Zachary J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[35] Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
Locke, Frederick L.
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric
Miklos, David B.
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick M.
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S277 - S278
[36] Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
Chavez, Julio C.
Jacobson, Caron A.
Sehgal, Alison R.
Neelapu, Sattva S.
Maloney, David G.
Salles, Gilles
William, Basem M.
Yang, Yin
Goyal, Lovely
Chou, Justin
Plaks, Vicki
Avanzi, Mauro P.
BLOOD, 2020, 136
[37] Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David B.
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick L.
BLOOD, 2020, 135 (23) : 2106 - 2109
[38] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Houot, Roch
Minnema, Monique
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
[39] Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
Ahmed, Sairah
Furqan, Fateeha
Strati, Paolo
Westin, Jason
Fayad, Luis
Hagemeister, Frederick B.
Lee, Hun Ju
Iyer, Swaminathan Padmanabhan
Nair, Ranjit
Nastoupil, Loretta J.
Parmar, Simrit
Rodriguez, Maria Alma
Samaniego, Felipe
Steiner, Raphael
Wang, Michael
Pinnix, Chelsea Camille
Flowers, Christopher
Horowitz, Sandra B.
Hawkins, Misha
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[40] Efficacy, safety, and covariates of outcomes with axicabtagene ciloleucel (axi-cel; KTE-C19) from ZUMA-1, a pivotal trial in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
Lin, Y.
Locke, L.
Neelapu, S. S.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J. S.
Elias, M.
Wiezorek, J.
Go, W. Y.
HUMAN GENE THERAPY, 2017, 28 (12) : A5 - A5

← 1 2 3 4 5 →